ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects

Inclusion Criteria: * Male and female subjects aged 18 years and over. * Subjects with a PED present for at least seven (7) days. * The defect may be of any size and must be measurable by slit lamp. * In the Investigator's opinion, the defect is persistent i.e., the defect has not shown improvement despite conventional treatment such as tear supplements and bandage contact lenses. * The original defect to the cornea must be the result of any injury, infection, disease or surgery to the eye. Exclusion Criteria: * Subjects currently being treated with cenegermin. * Subjects who require treatment with autologous serum eyedrops throughout the duration of the trial. If, in the opinion of the investigator, autologous serum eyedrop treatment can be safely stopped, the subject may be included in the clinical trial. * Subjects who require treatment with other amnion products throughout the duration of the trial. If, in the opinion of the investigator, the amniotic product treatment can be safely stopped, the subject may be included in the clinical trial. * Subject who requires treatment with amniotic membrane throughout the duration of the trial. If the amniotic membrane can be safely stopped, the subject may be included in the clinical trial. Note: The amniotic membrane must be removed at least one (1) day prior to the baseline visit. * Subjects who require treatment with bandage contact lens that cannot be removed at least 24 hours prior to screening. If the bandage contact lens …